Plain-English translation of NCT05997030 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This early feasibility study is testing a new treatment called Exablate low-intensity focused ultrasound (LIFU) for people with mild cognitive impairment caused by Alzheimer's disease. The focused ultrasound works as a neuromodulation tool — meaning it uses sound waves to gently stimulate brain activity. Researchers want to see if this treatment is safe and well-tolerated when used alongside other Alzheimer's medications.
Mild cognitive impairment is often an early sign of Alzheimer's disease, and current treatments have limited effectiveness. This trial exists to explore whether the new treatment could offer another option to help slow memory loss and thinking problems in people at this early disease stage.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the Exablate low-intensity focused ultrasound neuromodulation treatment as an add-on to any Alzheimer's medications you may already be taking. The study will monitor your safety and how well you tolerate the treatment. This is an early feasibility study with 15 participants, so the research team will be carefully tracking how your body and mind respond to this new approach.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States
Sponsor
Ali Rezai
Enrollment target
~15 participants
Started
October 2023
Primary completion
September 2026
Age range
45 Years – 85 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marc Haut, PhD
WVU Rockefeller Neuroscience Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.